Mechanistic description
TREM2 loss-of-function variants increase AD risk (~3-4x), and agonistic antibodies can enhance beneficial microglial responses including amyloid phagocytosis and plaque-associated microglial coverage. AL002 (Alector) in Phase 2 provides immediate clinical validation. Critical uncertainty remains regarding stage-dependency: TREM2 activation may benefit early amyloid phases but could worsen tau pathology or neuritic dystrophy in later disease stages. BBB penetration requires transporter-mediated delivery strategies.
Mechanism / pathway
- TREM2
- neurodegeneration
Evidence for (3)
TREM2 R47H variant increases AD risk
TREM2 required for microglial clustering around plaques
Anti-TREM2 antibody increases microglial coverage of plaques in 5xFAD mice
Evidence against (2)
TREM2 deletion can be protective in P301S tau mice
TREM2+ microglia show inflammatory genes (APOE, SPP1) that may worsen dystrophy
Evidence matrix
Supporting
- TREM2 R47H variant increases AD risk PMID:23376362
- TREM2 required for microglial clustering around plaques PMID:27477249
- Anti-TREM2 antibody increases microglial coverage of plaques in 5xFAD mice PMID:30755628
Contradicting
- TREM2 deletion can be protective in P301S tau mice PMID:29358985
- TREM2+ microglia show inflammatory genes (APOE, SPP1) that may worsen dystrophy PMID:29691401
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Agonistic antibodies targeting TREM2 to shift microglia toward neuroprotective…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-25193345a5
@misc{scidex_hypothesis_h2519334,
title = {Agonistic antibodies targeting TREM2 to shift microglia toward neuroprotective…},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-25193345a5},
note = {SciDEX artifact hypothesis:h-25193345a5}
}